GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Contineum Therapeutics Inc (NAS:CTNM) » Definitions » DeferredTaxAndRevenue

Contineum Therapeutics (Contineum Therapeutics) DeferredTaxAndRevenue : $0.00 Mil (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Contineum Therapeutics DeferredTaxAndRevenue?

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Contineum Therapeutics's current deferred tax and revenue for the quarter that ended in Mar. 2024 was $0.00 Mil.

Contineum Therapeutics DeferredTaxAndRevenue Historical Data

The historical data trend for Contineum Therapeutics's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Contineum Therapeutics DeferredTaxAndRevenue Chart

Contineum Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
DeferredTaxAndRevenue
0.08 - -

Contineum Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
DeferredTaxAndRevenue Get a 7-Day Free Trial - - - - -

Contineum Therapeutics DeferredTaxAndRevenue Related Terms

Thank you for viewing the detailed overview of Contineum Therapeutics's DeferredTaxAndRevenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Contineum Therapeutics (Contineum Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
10578 Science Center Drive, Suite 200, San Diego, CA, USA, 92121
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Contineum Therapeutics (Contineum Therapeutics) Headlines

From GuruFocus